NOVO NORDISK A S

Novo Nordisk A/S was formed in 1989 by a merger of two Danish companies, Nordisk Gentofte A/S and Novo Industri A/S. Novo Industri A/S was the continuing company and its name was changed to Novo Nordisk A/S. The business activities of Nordisk Gentofte were established in 1923 by August Krogh, H. C. Hagedorn and A. Kongsted, and the business activities of Novo Industri A/S were established in 1925 by Harald and Thorvald Pedersen. From the beginning, the business of both companies was the production and sale of insulin for the treatment of diabetes. Novo Nordisk’s B shares are listed on Nasdaq Copenhagen (NOVO-B). Its ADRs are listed on the New York Stock Exchange (NVO). Legal name: Novo Nordisk A/S Commercial name: Novo Nordisk Date of incorporation: 28 November 1931 Legal form of the Company: A Danish public limited liability company Legislation under which the Company operates: Danish law Country of incorporation: Denmark Reference is made to More information', on page 131 of our Annual Report 2025 for information on domicile. 4 Novo Nordisk Form 20-F 2025 ITEM 4 INFORMATION ON THE COMPANY Important events in 2025 Reference is made to Introducing Novo Nordisk’, pages 3-11 and 2025 performance and 2026 outlook’, pages 14-17 of our Annual Report 2025 for a description of important events in 2025. Capital expenditure in 2025, 2024 and 2023 For capital expenditure in 2025, 2024 and 2023, reference is made to the section entitled Cash flow and capital allocation’ on page 16 of our Annual Report 2025. No significant divestments took place in the period from 2023 2025.